Shukra Pharmaceuticals Limited

SHUKRAPHAR6

INE551C01028

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:30:56 01/07/2024 pm IST			5-day change	1st Jan Change
109.2 ^INR	-1.97%		-9.53%	+252.97%

29/05	Shukra Pharmaceuticals Limited Recommends Final Dividend for the Financial Year 2023- 24	CI
29/05	Shukra Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI

Shukra Pharmaceuticals Limited Appoints Arpita Shah as Company Secretary and Compliance Officer

December 07, 2019 at 06:11 pm IST

Shukra Pharmaceuticals Limited appointed Ms. Arpita Shah as Company Secretary and Compliance officer of the company at its Meeting of the Board of Director held on December 7, 2019.

Latest news about Shukra Pharmaceuticals Limited

Shukra Pharmaceuticals Limited Recommends Final Dividend for the Financial Year 2023- 24	29/05	CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	29/05	CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	12/02	CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11/11	CI
Shukra Pharmaceuticals Limited Announces the Resignation of Jivansingh Gangasingh Negi as Independent Director	06/23/06	CI
Shukra Pharmaceuticals Limited Announces Board Changes	16/23/16	CI
Shukra Pharmaceuticals Limited Announces Directorate Resignations	16/23/16	CI
Shukra Pharmaceuticals Limited Announces Executive Changes	12/23/12	CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	12/23/12	CI
Shukra Pharmaceuticals Limited Announces Resignation of Ashvin Trivedi as Non- Executive Director, Effective August 12, 2023	07/23/07	CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2023	29/23/29	CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	29/23/29	CI
Shukra Pharmaceuticals Limited Recommends Final Dividend for the Financial Year 2023	29/23/29	CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	14/23/14	CI
Shukra Pharmaceuticals Limited Announces Board Changes	12/22/12	CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	12/22/12	CI
Shukra Pharmaceuticals Limited Approves Final Dividend for the Financial Year 2021-22	01/22/01	CI
Shukra Pharmaceuticals Limited Recommends Final Dividend for the Financial Year 2021-22	05/22/05	CI
Shukra Pharmaceuticals to Raise Up to $2.4 Million from Equity Offering	25/22/25	MT
Shukra Pharmaceuticals Limited Appoints Rai Kavoorguthu Konark as Additional Independent Director	25/22/25	CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	06/22/06	CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	28/22/28	CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2022	28/22/28	CI
Shukra Pharmaceuticals Limited Recommends Final Dividend for the Financial Year 2021-22	28/22/28	CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	12/22/12	CI

Chart Shukra Pharmaceuticals Limited

Duration

Period

More charts

Shukra Pharmaceuticals Limited is an India-based company, which is engaged primarily in the business of manufacturing and marketing of pharmaceutical products. The Company operates in two sectors: pharmaceutical and laboratory. The Company's manufacturing plant is situated in Rakanpur, Gandhinagar. The Company's product portfolio includes antibiotics (penicillin), anti-biotics (cephalosporin), anti-biotics, macrolides, quinolones, anti-bacterial, anti-fungal, anti-malarial, anti-viral, anti-protozoal, anti-anthelmintic, sedative and tranquillizer, anti-depressant, anti-manic, anti-emetic, anti-ulcer, beta blockers, diuretics, analgesic, analgesic (NASID), muscle relaxants, anti-tuberculosis, vitamin products, anti-allergic, corticosteroids, hyper and hypoglycemic. The Company is engaged in manufacturing general formulations, such as tablets, capsules and small volume parenteral.

Sector

Pharmaceuticals

Calendar

02/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
SHUKRA PHARMACEUTICALS LIMITED	+252.97%	5.85Cr
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.70%	4.38TCr
OTSUKA HOLDINGS CO., LTD.	+30.16%	2.28TCr
CIPLA LIMITED	+18.68%	1.43TCr
ZYDUS LIFESCIENCES LIMITED	+54.86%	1.3TCr
THE MEDICINES COMPANY	-0.05%	678.76Cr
ONO PHARMACEUTICAL CO., LTD.	-11.72%	641.27Cr
STADA ARZNEIMITTEL	-8.87%	572.55Cr
ASPEN PHARMACARE HOLDINGS LIMITED	+14.65%	568.66Cr
GEDEON RICHTER	+9.49%	475.06Cr